
Doximity (DOCS) Stock Forecast & Price Target
Doximity (DOCS) Analyst Ratings
Bulls say
Doximity Inc. has reported a substantial growth of over 100% in its point-of-care (POC) and formulary offerings during the recent buying season, indicating strong demand for its services. The company's stock has shown a positive trend, increasing by 3.2% since September 8, reflecting investor confidence in its business prospects. Moreover, the guidance for the second quarter suggests a strong likelihood of achieving targets, with potential for further upside, supported by a boost in visibility from increased upfront buying.
Bears say
Doximity is facing a challenging outlook due to uncertain economic conditions, which have prompted its pharmaceutical clients to revise their budget forecasts downward for fiscal years 2023 and 2024. Additionally, the company's shares are considered expensive when compared to its software industry peers, raising concerns about potential volatility if performance does not meet elevated investor expectations. The heightened scrutiny on financial results may lead to further disappointment if Doximity fails to deliver positive outcomes or adjust its guidance upwards.
This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.
Doximity (DOCS) Analyst Forecast & Price Prediction
Start investing in Doximity (DOCS)
Order type
Buy in
Order amount
Est. shares
0 shares